CRVO (CervoMed Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by CRVO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-15 | JOSHUA S BOGER | Director | Buy | — | — |
| 2026-06-10 | Jeffrey V. Poulton | Director | A | — | — |
| 2026-06-10 | Sylvie Gregoire | Director | A | — | — |
| 2026-06-10 | JOHN J ALAM | CEO & President | A | — | — |
| 2026-06-10 | JOSHUA S BOGER | Director | A | — | — |
| 2026-06-10 | Marwan Sabbagh | Director | A | — | — |
| 2026-06-10 | FRANK ZAVRL | Director | A | — | — |
| 2026-06-10 | David Quigley | Director | A | — | — |
| 2026-06-10 | Jane H Hollingsworth | Director | A | — | — |
| 2026-02-13 | Kelly Blackburn | EVP, Clinical Development | A | — | — |
| 2026-02-13 | Mark De Rosch | EVP, RA and GA and PgM | A | — | — |
| 2026-02-13 | Sylvie Gregoire | Director | A | — | — |
| 2026-02-13 | WILLIAM ROBERT ELDER | CFO, GC & Secretary | A | — | — |
| 2026-02-13 | Matthew Winton | Chief Commercial and Business | A | — | — |
| 2026-02-13 | JOHN J ALAM | CEO & President | A | — | — |
| 2025-12-05 | David Quigley | Director | A | — | — |
| 2025-11-19 | Sylvie Gregoire | Director | Buy | — | — |
| 2025-11-19 | Matthew Winton | Chief Commercial and Business | Buy | — | — |
| 2025-11-19 | WILLIAM ROBERT ELDER | CFO, GC & Secretary | Buy | — | — |
| 2025-11-19 | JOHN J ALAM | CEO & President | Buy | — | — |
| 2025-11-17 | Matthew Winton | Chief Commercial and Business | Buy | — | — |
| 2025-11-17 | JOHN J ALAM | CEO & President | Buy | — | — |
| 2025-11-17 | Sylvie Gregoire | Director | Buy | — | — |
| 2025-11-13 | Sylvie Gregoire | Director | Buy | — | — |
| 2025-11-13 | JOHN J ALAM | CEO & President | Buy | — | — |
| 2025-11-13 | WILLIAM ROBERT ELDER | CFO, GC & Secretary | Buy | — | — |
| 2025-10-08 | Matthew Winton | Chief Commercial and Business | A | — | — |
| 2025-06-25 | JOHN J ALAM | CEO & President | A | — | — |
| 2025-06-25 | Marwan Sabbagh | Director | A | — | — |
| 2025-06-25 | JOSHUA S BOGER | Director | A | — | — |
| 2025-06-25 | Jeffrey V. Poulton | Director | A | — | — |
| 2025-06-25 | Jane H Hollingsworth | Director | A | — | — |
| 2025-06-25 | Sylvie Gregoire | Director | A | — | — |
| 2025-06-25 | FRANK ZAVRL | Director | A | — | — |
| 2025-05-14 | WILLIAM ROBERT ELDER | CFO, GC & Secretary | Buy | — | — |
| 2025-02-14 | WILLIAM ROBERT ELDER | CFO & GC | A | — | — |
| 2025-02-14 | JOHN J ALAM | CEO & President | A | — | — |
| 2025-02-14 | Robert Joseph Cobuzzi Jr. | Chief Operating Officer | A | — | — |
| 2025-02-14 | Kelly Blackburn | SVP, Clinical Development | A | — | — |
| 2025-02-14 | Sylvie Gregoire | Director | A | — | — |
| 2024-08-27 | WILLIAM ROBERT ELDER | CFO & GC | Buy | — | — |
| 2024-06-14 | JOHN J ALAM | CEO & President | A | — | — |
| 2024-06-14 | FRANK ZAVRL | Director | A | — | — |
| 2024-06-14 | Marwan Sabbagh | Director | A | — | — |
| 2024-06-14 | Jeffrey V. Poulton | Director | A | — | — |
| 2024-06-14 | Sylvie Gregoire | Director | A | — | — |
| 2024-06-14 | Jane H Hollingsworth | Director | A | — | — |
| 2024-06-14 | JOSHUA S BOGER | Director | A | — | — |
| 2024-02-28 | JOSHUA S BOGER | Director | MIXED | — | — |
| 2024-02-13 | JOSHUA S BOGER | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 2,012,682 | — |
| — | CEO & President | 1,496,578 | — |
| — | Director | 1,496,578 | — |
| — | Chief Commercial and Business | 15,000 | — |
| — | CFO, GC & Secretary | 12,500 | — |
| — | Director | 943 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CRVO quote page; the site-wide leaderboard is on the insider transactions hub.